HELICOBACTER PYLORI INFECTIONS
1
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
City TherapeuticsMA - Cambridge
1 program14-day vonoprazan-amoxicillin dual therapyN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2025
2026
Evergreen TherapeuticsHydrolyzed Lignin
City Therapeutics14-day vonoprazan-amoxicillin dual therapy
Clinical Trials (2)
Total enrollment: 70 patients across 2 trials
Lignin in Treatment of Helicobacter Pylori Infection
Start: Oct 2025Est. completion: Mar 202670 patients
Phase 3Active Not Recruiting
Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial
Start: Sep 2025Est. completion: Dec 2026
N/ANot Yet Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.